JP2019513804A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019513804A5 JP2019513804A5 JP2018554572A JP2018554572A JP2019513804A5 JP 2019513804 A5 JP2019513804 A5 JP 2019513804A5 JP 2018554572 A JP2018554572 A JP 2018554572A JP 2018554572 A JP2018554572 A JP 2018554572A JP 2019513804 A5 JP2019513804 A5 JP 2019513804A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- acceptable salt
- cycloalkyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 claims 31
- 125000000217 alkyl group Chemical group 0.000 claims 20
- 150000001875 compounds Chemical class 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 17
- 125000000753 cycloalkyl group Chemical group 0.000 claims 15
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 150000002431 hydrogen Chemical class 0.000 claims 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims 8
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 8
- 125000006417 CH Chemical group [H]C* 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- -1 2,4-difluorophenoxy Chemical group 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000026278 immune system disease Diseases 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 230000002757 inflammatory effect Effects 0.000 claims 4
- 230000001613 neoplastic effect Effects 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 150000001408 amides Chemical class 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- QOQREUBQBHJFNS-CQSZACIVSA-N (2R)-N-[2-(2-fluoro-6-methylphenoxy)-6-(1-methyl-6-oxopyridin-3-yl)pyrimidin-4-yl]butane-2-sulfonamide Chemical compound FC1=C(OC2=NC(=CC(=N2)NS(=O)(=O)[C@H](C)CC)C2=CN(C(C=C2)=O)C)C(=CC=C1)C QOQREUBQBHJFNS-CQSZACIVSA-N 0.000 claims 1
- QOQREUBQBHJFNS-AWEZNQCLSA-N (2S)-N-[2-(2-fluoro-6-methylphenoxy)-6-(1-methyl-6-oxopyridin-3-yl)pyrimidin-4-yl]butane-2-sulfonamide Chemical compound FC1=C(OC2=NC(=CC(=N2)NS(=O)(=O)[C@@H](C)CC)C2=CN(C(C=C2)=O)C)C(=CC=C1)C QOQREUBQBHJFNS-AWEZNQCLSA-N 0.000 claims 1
- FLNHKHUSIINDGR-UHFFFAOYSA-N 3,3,3-trifluoro-N-[2-(2-fluoro-6-methylphenoxy)-6-(1-methyl-6-oxopyridin-3-yl)pyrimidin-4-yl]propane-1-sulfonamide Chemical compound FC1=C(OC2=NC(=CC(=N2)NS(=O)(=O)CCC(F)(F)F)C2=CN(C(C=C2)=O)C)C(=CC=C1)C FLNHKHUSIINDGR-UHFFFAOYSA-N 0.000 claims 1
- BPLBOVPXBOLUTH-UHFFFAOYSA-N 4,4,4-trifluoro-N-[2-(2-fluoro-6-methylphenoxy)-6-(1-methyl-6-oxopyridin-3-yl)pyrimidin-4-yl]butane-1-sulfonamide Chemical compound FC1=C(OC2=NC(=CC(=N2)NS(=O)(=O)CCCC(F)(F)F)C2=CN(C(C=C2)=O)C)C(=CC=C1)C BPLBOVPXBOLUTH-UHFFFAOYSA-N 0.000 claims 1
- 125000006416 CBr Chemical group BrC* 0.000 claims 1
- 125000006414 CCl Chemical group ClC* 0.000 claims 1
- 125000006415 CF Chemical group FC* 0.000 claims 1
- NJQHAFKVBSGXRC-UHFFFAOYSA-N N-[2-(2,4-dichloro-6-methylphenoxy)-6-(1,5-dimethyl-6-oxopyridin-3-yl)pyrimidin-4-yl]propane-2-sulfonamide Chemical compound ClC1=C(OC2=NC(=CC(=N2)NS(=O)(=O)C(C)C)C2=CN(C(C(=C2)C)=O)C)C(=CC(=C1)Cl)C NJQHAFKVBSGXRC-UHFFFAOYSA-N 0.000 claims 1
- FAVDKQWNPLKKFB-UHFFFAOYSA-N N-[2-(2-chloro-6-methylphenoxy)-6-(1,5-dimethyl-6-oxopyridin-3-yl)pyrimidin-4-yl]butane-1-sulfonamide Chemical compound ClC1=C(OC2=NC(=CC(=N2)NS(=O)(=O)CCCC)C2=CN(C(C(=C2)C)=O)C)C(=CC=C1)C FAVDKQWNPLKKFB-UHFFFAOYSA-N 0.000 claims 1
- KIUXMESFQFPSQB-UHFFFAOYSA-N N-[2-(2-fluoro-6-methylphenoxy)-6-(1-methyl-6-oxopyridin-3-yl)pyrimidin-4-yl]butane-1-sulfonamide Chemical compound FC1=C(OC2=NC(=CC(=N2)NS(=O)(=O)CCCC)C2=CN(C(C=C2)=O)C)C(=CC=C1)C KIUXMESFQFPSQB-UHFFFAOYSA-N 0.000 claims 1
- 210000000068 Th17 cell Anatomy 0.000 claims 1
- 230000003915 cell function Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022013404A JP2022064967A (ja) | 2016-04-18 | 2022-01-31 | 治療用化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662324279P | 2016-04-18 | 2016-04-18 | |
| US62/324,279 | 2016-04-18 | ||
| PCT/US2017/027815 WO2017184462A1 (en) | 2016-04-18 | 2017-04-14 | Therapeutic compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022013404A Division JP2022064967A (ja) | 2016-04-18 | 2022-01-31 | 治療用化合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019513804A JP2019513804A (ja) | 2019-05-30 |
| JP2019513804A5 true JP2019513804A5 (cg-RX-API-DMAC10.html) | 2020-05-21 |
Family
ID=60039979
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554572A Pending JP2019513804A (ja) | 2016-04-18 | 2017-04-14 | 治療用化合物 |
| JP2022013404A Pending JP2022064967A (ja) | 2016-04-18 | 2022-01-31 | 治療用化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022013404A Pending JP2022064967A (ja) | 2016-04-18 | 2022-01-31 | 治療用化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10202360B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3445750A4 (cg-RX-API-DMAC10.html) |
| JP (2) | JP2019513804A (cg-RX-API-DMAC10.html) |
| AR (1) | AR108223A1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU2017252276A1 (cg-RX-API-DMAC10.html) |
| TW (1) | TW201739744A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2017184462A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10617680B2 (en) | 2017-04-18 | 2020-04-14 | Celgene Quanticel Research, Inc. | Therapeutic compounds |
| CN110016014B (zh) * | 2018-01-08 | 2023-02-17 | 中国科学院上海药物研究所 | Ezh2抑制剂及其制备和抗肿瘤治疗中的应用 |
| CN112165944B (zh) | 2018-03-29 | 2024-04-09 | 德州大学系统董事会 | 转录激活蛋白的咪唑并哌嗪抑制剂 |
| US10899769B2 (en) | 2018-04-06 | 2021-01-26 | Board Of Regents, The University Of Texas System | Imidazopiperazinone inhibitors of transcription activating proteins |
| CN114286818B (zh) | 2019-07-02 | 2024-09-20 | 诺维逊生物股份有限公司 | 作为bet抑制剂的杂环化合物 |
| US20230174545A1 (en) * | 2020-04-29 | 2023-06-08 | Nuvation Bio Inc. | Heterocyclic compounds as bet inhibitors |
| WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
| US11753413B2 (en) | 2020-06-19 | 2023-09-12 | Incyte Corporation | Substituted pyrrolo[2,1-f][1,2,4]triazine compounds as JAK2 V617F inhibitors |
| WO2022006456A1 (en) | 2020-07-02 | 2022-01-06 | Incyte Corporation | Tricyclic pyridone compounds as jak2 v617f inhibitors |
| AU2021300429A1 (en) | 2020-07-02 | 2023-02-16 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| WO2022046989A1 (en) | 2020-08-27 | 2022-03-03 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| CN112225738B (zh) * | 2020-12-18 | 2021-04-13 | 北京鑫开元医药科技有限公司 | 作为tlr8激动剂的化合物、其制备方法、组合物及其用途 |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| WO2022182839A1 (en) | 2021-02-25 | 2022-09-01 | Incyte Corporation | Spirocyclic lactams as jak2 v617f inhibitors |
| CN115703760B (zh) * | 2021-08-11 | 2024-05-31 | 山东大学 | 2,4-二取代嘧啶类细胞周期蛋白依赖性激酶酶抑制剂及其制备方法和应用 |
| CA3237199A1 (en) | 2021-11-02 | 2023-05-11 | Flare Therapeutics Inc. | Pparg inverse agonists and uses thereof |
| CN119173514A (zh) | 2022-03-17 | 2024-12-20 | 因赛特公司 | 作为jak2 v617f抑制剂的三环脲化合物 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2011970A1 (en) | 1970-03-13 | 1971-11-18 | CH. Boehringer Sohn, 6507 Ingelheim | Imidazo-(1, 2-a)- pyrimidines prepn |
| US3635667A (en) | 1970-07-23 | 1972-01-18 | Fmc Corp | Drycleaning with hydrogen peroxide |
| BE786028A (fr) | 1971-07-08 | 1973-01-08 | Boehringer Sohn Ingelheim | 2,3-dihydro-oxo-imidazo(1,2-a)-pyrimidines, leurs sels d'addition avec des acides et procedes pour les fabriquer |
| DE2356005A1 (de) | 1973-11-09 | 1975-05-22 | Boehringer Sohn Ingelheim | Neue 7-amino-imidazo eckige klammer auf 1,2-a eckige klammer zu pyrimidine, diese enthaltende arzneimittel sowie verfahren zu deren herstellung |
| AU577105B2 (en) | 1985-04-02 | 1988-09-15 | T.P.O. :Pharmachim: | Acylaminic penicillin derivatives |
| US6117940A (en) | 1997-10-17 | 2000-09-12 | Mjalli; Adnan M. M. | Amino-ketone solid support templates |
| EP1556381B1 (en) | 2002-09-26 | 2008-02-20 | Pfizer Limited | Pyrazole amides for treating hiv infections |
| JP2005089352A (ja) | 2003-09-16 | 2005-04-07 | Kissei Pharmaceut Co Ltd | 新規なイミダゾ［１，５−ａ］ピラジン誘導体、それを含有する医薬組成物およびそれらの用途 |
| EP1667982B1 (en) | 2003-09-23 | 2013-07-31 | Merck Sharp & Dohme Corp. | Isoquinolinone potassium channel inhibitors |
| KR100703068B1 (ko) | 2003-12-30 | 2007-04-05 | 에스케이케미칼주식회사 | 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물 |
| WO2005095384A1 (en) | 2004-04-01 | 2005-10-13 | Astellas Pharma Inc. | Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists |
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| KR100781704B1 (ko) | 2005-04-20 | 2007-12-03 | 에스케이케미칼주식회사 | 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물 |
| US7452892B2 (en) | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
| EP2385047B1 (en) | 2005-07-26 | 2013-05-29 | Sanofi | Piperidinyl-substituted isoquinolone derivatives |
| ES2372067T3 (es) | 2005-07-26 | 2012-01-13 | Sanofi | Derivados de ciclohexilamina isoquinolona como inhibidores de la rho-quinasa. |
| US20070099911A1 (en) | 2005-10-28 | 2007-05-03 | Wyeth | Pyrroloquinolinone derivatives as 5-hydroxytryptamine-6 ligands |
| WO2008039882A1 (en) * | 2006-09-30 | 2008-04-03 | Sanofi-Aventis U.S. Llc | A combination of niacin and a prostaglandin d2 receptor antagonist |
| RU2455302C2 (ru) | 2006-12-27 | 2012-07-10 | Санофи-Авентис | ЗАМЕЩЕННЫЕ ИЗОХИНОЛИНОВЫЕ И ИЗОХИНОЛИНОНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ |
| HRP20100705T1 (hr) | 2006-12-27 | 2011-01-31 | Sanofi-Aventis | Cikloalkilaminski supstituirani izokinolinski i izokinolinonski derivati |
| CN101595094B (zh) | 2006-12-27 | 2013-02-20 | 塞诺菲-安万特股份有限公司 | 环烷基胺取代的异喹诺酮衍生物 |
| TW200906825A (en) * | 2007-05-30 | 2009-02-16 | Scripps Research Inst | Inhibitors of protein kinases |
| WO2009029214A1 (en) | 2007-08-23 | 2009-03-05 | Amgen Inc. | Isoquinolone derivatives as phosphodiesterase 10 inhibitors |
| EP2250176B1 (en) | 2008-01-30 | 2012-08-01 | Cephalon, Inc. | Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands |
| ES2389478T3 (es) | 2008-06-25 | 2012-10-26 | Bristol-Myers Squibb Company | Derivados de dicetopiperidina como inhibidores de la fijación del VIH |
| EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
| RU2615130C2 (ru) | 2009-10-06 | 2017-04-04 | Милленниум Фармасьютикалз, Инк | Гетероциклические соединения, используемые в качестве ингибиторов pdk1 |
| ES2792799T3 (es) | 2010-06-28 | 2020-11-12 | Merck Patent Gmbh | [1,8]naftiridinas 2,4-diaril-sustituidas como inhibidores de quinasas para su uso contra el cáncer |
| JPWO2012020786A1 (ja) * | 2010-08-11 | 2013-10-28 | 日本新薬株式会社 | 医薬組成物 |
| WO2012101654A2 (en) * | 2011-01-25 | 2012-08-02 | Sphaera Pharma Pvt. Ltd | Novel triazine compounds |
| CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CN104093716B (zh) | 2011-10-31 | 2017-06-23 | 克赛农制药股份有限公司 | 联芳醚磺酰胺化合物及其作为治疗剂的用途 |
| CN103183675A (zh) | 2011-12-27 | 2013-07-03 | 山东轩竹医药科技有限公司 | 磷酸二酯酶-4抑制剂 |
| WO2013180183A1 (ja) * | 2012-05-30 | 2013-12-05 | 日本新薬株式会社 | 芳香族複素環誘導体及び医薬 |
| CN105073744B (zh) * | 2012-12-21 | 2019-11-08 | 齐尼思表观遗传学有限公司 | 作为溴结构域抑制剂的新型杂环化合物 |
| JP2016512543A (ja) * | 2013-03-12 | 2016-04-28 | アッヴィ・インコーポレイテッド | ジヒドロ−ピロロピリジノンブロモドメイン阻害剤 |
| AU2014230816B9 (en) * | 2013-03-14 | 2016-12-15 | Glaxosmithkline Intellectual Property (No.2) Limited | Furopyridines as bromodomain inhibitors |
| KR20160002850A (ko) * | 2013-05-01 | 2016-01-08 | 에프. 호프만-라 로슈 아게 | C-연결된 헤테로사이클로알킬 치환된 피리미딘 및 이의 용도 |
| EP3640241B1 (en) * | 2013-10-18 | 2022-09-28 | Celgene Quanticel Research, Inc. | Bromodomain inhibitors |
| PL3092227T3 (pl) * | 2014-01-09 | 2018-12-31 | Orion Corporation | Bicykliczne pochodne heterocykliczne jako inhibitory bromodomeny |
| CA2948601A1 (en) * | 2014-06-04 | 2015-12-10 | Thomas Helledays Stiftelse For Medicinsk Forskning | Mth1 inhibitors for treatment of inflammatory and autoimmune conditions |
| CA3030581C (en) * | 2016-07-18 | 2021-05-25 | National Institute Of Biological Sciences, Beijing | Apoptosis inhibitors |
-
2017
- 2017-04-14 AU AU2017252276A patent/AU2017252276A1/en not_active Abandoned
- 2017-04-14 JP JP2018554572A patent/JP2019513804A/ja active Pending
- 2017-04-14 EP EP17786389.1A patent/EP3445750A4/en not_active Withdrawn
- 2017-04-14 WO PCT/US2017/027815 patent/WO2017184462A1/en not_active Ceased
- 2017-04-17 US US15/488,674 patent/US10202360B2/en active Active
- 2017-04-18 AR ARP170100985A patent/AR108223A1/es unknown
- 2017-04-18 TW TW106112891A patent/TW201739744A/zh unknown
-
2022
- 2022-01-31 JP JP2022013404A patent/JP2022064967A/ja active Pending